ClinicalTrials.gg
RecruitingNCT07022184LIDIASUpdated Dec 22, 2025

Lifestyle Intervention for Symptoms of Depression wIth App Support in General Practice

An interventional study of Personalized Lifestyle Intervention in Depressive/Anxiety Symptoms and Depressive Disorder, sponsored by Radboud University Medical Center. Recruiting at 3 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-22.

Primary conditionDepressive DisorderRegistry: Anxiety DisordersReclassifiedWhy we changed it
Registry
Anxiety Disorders — the first condition term the registry derived for this study.
ClinicalTrials.gg
Depressive Disorder
Why
  1. The registry often attaches Anxiety Disorders to studies about something else, and this study's title and listed conditions do not name it.
  2. The study's listed conditions name Depressive Disorder.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Radboud University Medical Center · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
216
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Depressive Disorder with a site in Netherlands — 7 open to participants now, 9 under way, none of them phase 3. Depressive Disorder · Netherlands.

Planned enrollment
5th of 16
216 · median 151
Started
2025
with 1 other
No phase
9 of 18
6 open now
Registered
17th of 18
by date
Lead sponsor
3 of 18
Radboud University Medical Center

Among the 18 studies in Depressive Disorder with a site in Netherlands, this one is the 5th largest by planned enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2025, is one of 9 with no phase, and was the 17th registered.

Depressive Disorder

857 studies on the registry are indexed under Depressive Disorder; 160 are open to participants now.

Browse Depressive Disorder studies →

Open to participants now

7 of the 18 studies in Depressive Disorder with a site in Netherlands are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 116 Depressive Disorder studies recruiting now, 44 (38%) set no upper age limit and 66 (57%) stop at 75 or younger; 24 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Depressive Disorder with a site in Netherlands, or all of them as a file.
02

Study summary

The goal of this clinical trial is to find out whether a smartphone app can help reduce symptoms of depression by supporting healthy lifestyle changes and encouraging self-monitoring in adults who visit their general practitioner with symptoms of depression.

The main questions this study aims to answer are:

Does a personalized lifestyle intervention delivered through the app, in addition to regular care, reduce depression symptoms more effectively than regular care alone? Is this approach more cost-effective than regular care alone?

Researchers will compare patients who use the app alongside their regular care to patients who receive regular care without the app, to see whether the app leads to better outcomes.

Participants who use the app will:

Complete a lifestyle questionnaire focused on six themes: mental wellbeing, use of harmful substances, social relationships, healthy eating, sleep, and physical activity.

Set personal goals based on their results and receive tailored lifestyle advice.

Track their depression symptoms regularly within the app to support ongoing care.

Have follow-up conversations with their general practitioner or mental health nurse to discuss their progress.

Fill out questionnaires about their symptoms and experiences during the study.

03

Conditions studied

  • Depressive/Anxiety Symptoms
  • Depressive Disorder

Browse trials for

Keywords

  • Personalized lifestyle intervention
  • eHealth
  • Measurement-based care
  • Depression symptomatology
  • Cluster randomized trial
  • General practice
  • Lifestyle changes
  • Mental health support
  • Primary care
04

In context

Depressive Disorder Reclassified

857 studies on the registry are indexed under Depressive Disorder; 160 are open to participants now.

This study's planned enrollment of 216 is above the median of 87 across 691 interventional studies indexed under Depressive Disorder.

Browse Depressive Disorder studies →

Lead sponsor

Radboud University Medical Center is the lead sponsor of 986 studies on the registry; 135 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Compared within Depressive Disorder, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Anxiety Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Currently experiencing an episode of symptoms of depression and receiving treatment for this episode from their GP or GP-MHW for less than six months
  • Have a smartphone
  • Be proficient in Dutch

Exclusion criteria

Exclusion Criteria:

  • Severe mental illness (such as psychosis or bipolar disorder)
  • Severe alcohol or drug addiction requiring specialized secondary care
  • High suicide risk
  • moderate to severe cognitive impairment (as determined by the GP)

Patients who visit their GP for depressive symptoms but with a PHQ-9 of \<5 at baseline are allowed to use the PLI, but will not be included in the primary analysis.

06

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
216 participants (estimated)

Study arms

  • No intervention
    Care As Usual (CAU)

    The control group, receiving care as usual, will use a version of the Patient Journey App that only displays study questionnaires and sends reminders to complete them at the start of the study, and again at 3 and 6 months. Every 6 weeks, depression symptoms are measured. Patients can view their depression questionnaire results (PHQ-9; Patient Health Questionnaire-9) in a graph within the app. General practitioners and mental health nurses will not have access to the app. At 12 months, all participants will be invited to complete an optional final questionnaire about (cost-)effectiveness to assess the long-term impact of the intervention.

  • Experimental
    Personalized Lifestyle Intervention

    The intervention group will receive the personalized lifestyle intervention (PLI) in addition to care as usual. The PLI consists of the combined use of the Patient Journey App and regular treatment provided by the general practitioner or mental health nurse in general practice. Patients, general practitioners and mental health nurses will have access to the app to monitor patient progress and outcomes (symptoms of depression and anxiety). Study questionnaires will be completed at the start of the study (baseline), and again at 3, 6, and optionally 12 months after enrollment. Every 6 weeks, depression symptoms are measured.

    Device: Personalized Lifestyle Intervention

Interventions

  • DevicePersonalized Lifestyle Intervention

    The personalized lifestyle intervention (PLI) consists of the combined use of the Patient Journey App (PJA) alongside care provided by the general practitioner or mental health nurse. The Patient Journey App integrates four digital health tools within a single smartphone application: 1. A brief lifestyle questionnaire covering six key areas: mental wellbeing, minimizing harmful substance use, social relationships, healthy eating, sleep, and physical activity. 2. A personalized summary of the questionnaire results, which supports the formulation of two personal lifestyle goals. 3. Tailored information and advice about lifestyle, including suggested interventions, based on the patient's personal goals. 4. Monitoring of depression symptoms over time to support measurement-based care. General practitioners and mental health nurses will have access to the app to monitor patient progress and outcomes.

    Also known as: Patient Journey App, Lifestyle App, PLI

07

What researchers measure

Primary outcomes

  1. Cost-effectiveness of the Personalized Lifestyle Intervention at 6 months after baseline

    To assess the PLI's cost-effectiveness from a societal perspective, the Treatment Inventory of Costs in Patients with psychiatric disorders (TIC-P) will be used. The main outcome in the cost-effectiveness analysis is Quality-Adjusted Life-Years (QALYs) based on the EQ-5D-5L, measuring general quality of life. Also, additional treatments are measured within the TIC-P, for secondary analysis on additional care.

    Time frame: Baseline to 6 months

  2. Change in quality of life using the EQ-5D-5L

    Change in quality of life will be assessed using the EQ-5D-5L. This tool consists of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, with each rated on a 5-level scale. The EQ-5D-5L also includes a visual analog scale (VAS) to assess overall health. Higher scores indicate better quality of life, while lower scores reflect greater limitations or discomfort. This measure helps track changes in health status and overall quality of life over time.

    Time frame: Baseline to 6 months

  3. Change from baseline in the mean depression severity score measured by the PHQ-9 at 6 months after baseline

    To evaluate the effectiveness of the PLI on depression symptomatology, general symptoms of depression will be assessed using the Patient Health Questionnaire-9 (PHQ-9). The PHQ-9 is a 9-item self-reported questionnaire assessing the severity of depression symptomatology. The PHQ-9 is brief, easy to complete, and takes only a few minutes to fill out. The total score ranges from 0 to 27. Scores are interpreted as follows: 0-4 indicates minimal or no depression, 5-9 mild depression, 10-14 moderate depression, 15-19 moderately severe depression, and 20-27 severe depression. Higher scores suggest more severe symptoms, and professional treatment is recommended as the score increases.

    Time frame: Baseline to 6 months.

Secondary outcomes

  1. Change in the severity of anxiety symptoms: GAD-7 (Generalized Anxiety Disorder-7)

    To measure the severity of anxiety symptoms, the GAD-7 (Generalized Anxiety Disorder-7) will be used

    Time frame: Baseline to 3 , 6 and 12 months

  2. Changes in quality of life according to the Recovering Quality of Life (ReQol)

    Quality of life is measured using the Recovering Quality of Life (ReQol) questionnaire, a patient-reported outcome measure specifically developed for individuals with various mental health conditions. The ReQol provides a total score ranging from 0 to 80, with higher scores reflecting a better quality of life and overall recovery outcome.

    Time frame: Baseline to 3, 6 and 12 months

  3. Change in use of antidepressants

    Use of antidepressants, when started/ended, type, dosage, and at follow-up: inquire about changes.

    Time frame: Baseline to 3 and 6 months

  4. Change in use of anxiolytics

    Use of anxiolytics by self-reported questions about the use of sedatives/sleep medication, when started/ended, frequency of use, type, dosage, and at follow-up: inquire about changes.

    Time frame: Baseline to 3 and 6 months

  5. Change in lifestyle measures at month 6

    Self-constructed questions about the daily lifestyle habits of all participants. The lifestyle components addressed include smoking, alcohol consumption, drug use, sleep duration, adherence to the Dutch Physical Activity Guidelines according to the Dutch National Institute for Public Health and the Environment (RIVM), and nutrition based on the dietary recommendations of the Netherlands Nutrition Centre.

    Time frame: Baseline to 6 months

  6. Change in BMI

    Weight and height will be combined to report BMI (Body Mass Index) in kg/m\^2.

    Time frame: Baseline to 6 months

  7. Change in lifestyle satisfaction measures at month 6 (intervention arm)

    In the intervention group, self-constructed questions about lifestyle are used to measure a patient's satisfaction with specific lifestyle components on a scale from 0 to 10, where 10 indicates the highest level of satisfaction. The lifestyle components include mental wellbeing, minimizing harmful substances, social relationships, healthy eating, sleep, and physical activity. It is possible that someone smokes but is currently satisfied with this and does not wish to make any changes. The intervention is not intended to impose certain behaviors but rather to address the lifestyle components that the individual is willing and motivated to improve, with the ultimate goal of reducing depressive symptoms. These questions collectively provide an overview that the healthcare provider and patient can use together to set achievable goals. In the control group, this questionnaire will only be completed at month 6 of the study.

    Time frame: Baseline (intervention only) and 6 months (both groups)

  8. Patient satisfaction: CQi (Consumer Quality Index)

    The Consumer Quality Index (CQI) is a 16-item questionnaire that evaluates patient experiences and satisfaction across various dimensions, such as communication, access to care, and treatment outcomes. The CQI helps healthcare providers track patient experiences and identify opportunities for enhancing care. It has a 5 point scale. The last item is a scoring item for overall treatment satisfaction. Higher scores indicate better satisfaction, while lower scores highlight areas for improvement.

    Time frame: At 6 months

  9. Change in patient-doctor relationship: PDRQ-9

    The Patient-Doctor-Relationship Questionnaire (PDRQ-9) is a patient-reported outcome measure used to assess the quality of the therapeutic relationship between patients and their healthcare providers, such as general practitioners (GPs) or mental health nurses (GP-MHNs). The questionnaire evaluates key aspects of the patient-provider interaction, helping to capture the perceived level of trust, support, and communication. The score ranges from 9 to 45, higher score indicating a more positive relationship according to the patient.

    Time frame: Baseline to 6 months

  10. Change in social support: SSL12 (Social Support List-12)

    Social support will be measured using the SSL12 (Social Support List-12) questionnaire. This validated tool assesses perceived social support across various domains, such as emotional, practical, and informational support. Higher scores indicate greater perceived social support, while lower scores suggest limited support. The SSL12 helps evaluate the level of social assistance individuals feel they receive and can track changes in social support over time.

    Time frame: Baseline to 6 months

  11. PHQ-9 at 3 and 12 months

    Secondary analysis of PHQ-9 outcomes. To evaluate the effectiveness of the PLI on depression symptomatology, general symptoms of depression will be assessed using the Patient Health Questionnaire-9 (PHQ-9) every 6 weeks. The PHQ-9 is a 9-item self-reported questionnaire assessing the severity of depression symptomatology. The PHQ-9 is brief, easy to complete, and takes only a few minutes to fill out. The total score ranges from 0 to 27. Scores are interpreted as follows: 0-4 indicates minimal or no depression, 5-9 mild depression, 10-14 moderate depression, 15-19 moderately severe depression, and 20-27 severe depression. Higher scores suggest more severe symptoms, and professional treatment is recommended as the score increases.

    Time frame: Baseline to 6 weeks, 3 months and 12 months

  12. Cost-effectiveness at 3 months and at 12 months

    To assess the PLI's cost-effectiveness from a societal perspective, the Treatment Inventory of Costs in Patients with psychiatric disorders (TIC-P) will be used. The main outcome in the cost-effectiveness analysis is Quality-Adjusted Life-Years (QALYs) based on the EQ-5D-5L, measuring general quality of life. At 3 and 12 months, an incremental analysis is done in addition to the cost-effectiveness at 6 months

    Time frame: baseline to 3 and 12 months

Other outcomes

  1. Socio-demographics at baseline

    Baseline demographics include gender, age, education level, employment status and ethnicity.

    Time frame: At baseline

  2. Threatening Experiences: LTE

    The List of Threatening Experiences (LTE, developed bij Brugha) measures the occurrence of 12 major categories of stressful life events (did you experience this: No, yes in the last 6 months, yes longer ago) The Dutch translation includes an additional thirteenth question: "Did you experience any other major severe negative events (yes/no)? If yes, briefly describe what happened?" The questionnaire is offered at baseline, and at 6 months a shorter version (did you experience this in the last 6 months?). Item scores are summed to derive a total score. Higher score indicates more threatening experiences.

    Time frame: At enrollment and at 6 months

  3. History of depression and previous psychological treatment

    History of depression and previous psychological treatment are assessed through self-reported questions. These include the number of previous depressive episodes treated, the number of hospitalizations for depression in a psychiatric hospital or mental health institution, age of onset, duration of the current episode (when it began), family history of depression, and any previous psychological treatment or psychotherapy.

    Time frame: At baseline

  4. Chronic diseases: TIC-P

    Chronic diseases will be evaluated using questions of the TIC-P questionnaire e.g., health status, lung diseases, heart diseases, blood vessels, diabetes, stroke, joint degeneration, rheumatism, cancer, high blood pressure, and other diseases.

    Time frame: At baseline

  5. Psychiatric comorbidities: LIDAS items (LIfetime Depression Assessment Self-report), adjusted.

    This questionnaire comprises questions about psychiatric diagnoses and treatment (in the last 6 months , ever or never), other than depression.

    Time frame: Baseline to month 6

  6. Meta-data Patient Journey App during study

    Meta-data in the Patient Journey App will be tracked and analyzed. Meta-data includes application usage data such as the frequency of app openings, the number of times patients access information, and which features or sections are most frequently used or viewed.

    Time frame: At 6 and 12 months

  7. Acceptability and usability of the app: modified MAUQ (intervention arm)

    The mHealth App Usability Questionnaire (MAUQ) is a 21-item survey scored on a 7 point likert scale from 1 (disagree) to 7 (agree) with higher scores indicative of higher usability. For this study, the subscales MAUQ-E (8 items on Ease of use and satisfaction) and MAUQ-U (7 items on Usefulness) will be used.

    Time frame: At 6 months (intervention arm only).

08

Study locations

3 of 3 sites recruiting
09

References and documents

Publications

  • Jagtenberg EM, Ligthart SA, Muilwijk OG, Akkermans RP, Spoelder M, Burger H, Maarsingh OR, Assendelft WJJ, Hartman TCO. Cost-effectiveness of a smartphone-based personalized lifestyle intervention for symptoms of depression in primary care: protocol for a cluster-randomized controlled trial (LIDIAS). Trials. 2026 May 20;27(1):490. doi: 10.1186/s13063-026-09786-1. PubMed 42157297 ↗

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Nov 2026, 17 months after the start.

Of 261 non-industry interventional studies with no phase under Depressive Disorder, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 45. This study's planned 17 months is below that.

Counting every sponsor, half of 276 studies reached it within 29 months; a quarter within 15 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2025
First posted
Jun 15, 2025
StartActual
Jun 17, 2025
Primary completionEst.
Nov 2026
CompletionEst.
Feb 2027
Last update
Dec 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07022184
Collaborators
Ixta Noa, Hogeschool van Arnhem en Nijmegen (HAN), Pro Persona Mental Health Care Foundation, Amsterdam UMC, Interactive Studios, University Medical Center Groningen
Responsible party
Sponsor
First posted
Jun 15, 2025
Start date
Jun 17, 2025
Primary completion
Nov 2026 (estimated)
Completion
Feb 2027 (estimated)
Last update
Dec 22, 2025

Study contacts

Eline Jagtenberg
Contact
eline.jagtenberg@radboudumc.nl
0652902132
Suzanne Ligthart
Contact
suzanne.ligthart@radboudumc.nl

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion